EpiVax, Inc. - Informatics and Immunology
  • Our Company
    • Company Overview
    • Corporate Responsibility
    • Mission, Vision & Values
    • Team
    • Careers
    • Contact Us
  • Pipeline
    • Pipeline Overview
    • EPV-CoV19: HCW Vaccine
    • BioDefense Vaccines
    • Tregitope: Immunomodulation Power Tool
    • Deimmunization Projects
  • Vaccine Services
    • Vaccine Services
    • COVID-19 Coverage
  • Immunogenicity Assessment
    • Immunogenicity Assessment Overview
    • ISPRI Web-based Immunogenicity Assessment
    • PreDeFT Analysis
    • JanusMatrix Analysis
    • High Throughput Antibody Immunogenicity Analysis
    • PANDA Screening
    • ISPRI for Host Cell Proteins
    • iVAX: Web-based Vaccine Design
    • PreVAX Analysis
  • Deimmunization
  • Lab Services
    • Lab Services Overview
    • T Cell Assays
    • HLA Binding Assays
    • HLA Transgenic Mice
    • In Vitro Immunization Protocol (IVIP)
  • Press Room
    • Press Room
    • Events
      • Webinars
    • Publication & Poster Search
    • Client Testimonials
    • Thinking Out Loud (Blog)
  • Contact Us
Select Page
Checkpoint Inhibitors can be Immunogenic, Too!

Checkpoint Inhibitors can be Immunogenic, Too!

by Annie De Groot | Oct 26, 2017 | EpiVax Immunoncology, Thinking Out Loud -Blog

Yes, wonder drugs though they are, checkpoint inhibitors (a.k.a CPI) drive anti-drug antibodies (ADA) too. We’ve been concerned for a while that “releasing the brakes” will drive T cell response to CPI, and have been watching to see what happens....
EpiVax Launches Precision Immunotherapy Venture

EpiVax Launches Precision Immunotherapy Venture

by Annie De Groot | Sep 25, 2017 | EpiVax Immunoncology, News

EpiVax Oncology Press Release Sept 25 2017 Sept 25, 2017 (Providence, RI) – EpiVax, Inc., a leader in the fields of immunogenicity assessment, vaccine design, and immune-engineering today announced the launch of EpiVax Oncology Inc., a company focused on the...
EpiVax and EpiVax Oncology: Ready to Take on Cancer

EpiVax and EpiVax Oncology: Ready to Take on Cancer

by Katie Porter | Aug 22, 2017 | EpiVax Immunoncology, Featured, News, Thinking Out Loud -Blog

EpiVax has carved out a niche in the biotech and immunoinformatics industry with our innovative tools and discoveries. Well-situated on a trajectory Dr. De Groot described as “upward and stable,” EpiVax is now gearing up to launch a venture-backed spinoff called...
EpiVax Awarded New “Innovation Voucher”

EpiVax Awarded New “Innovation Voucher”

by epivax3 | Aug 3, 2017 | EpiVax Immunoncology, News, Thinking Out Loud -Blog

Accelerating the Development of a Game Changing Cancer Therapy PROVIDENCE, R.I., Aug. 3, 2017 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today announced it received funding from the Rhode Island Commerce Corporation to accelerate the development of...
Will EpiVax Tools be the Ancer to Cancer?

Will EpiVax Tools be the Ancer to Cancer?

by Annie De Groot | Jan 2, 2017 | EpiVax Immunoncology, News, Thinking Out Loud -Blog

EpiVax Oncology – New Year, New Endeavor! A nice story in ConvergenceRI that describes the rapid growth of EpiVax and our decision to invest in a new spin-out company in 2017: Welcome EpiVax Oncology! Annie was interviewed by Richard Asinof about “EpiVax...
The Ancer to Cancer: A computational pipeline for personalized cancer vaccine design

The Ancer to Cancer: A computational pipeline for personalized cancer vaccine design

by Annie De Groot | Dec 11, 2016 | EpiVax Immunoncology, Featured, News, Thinking Out Loud -Blog

Building on 18 years of commercially successful research and development in the field of computational immunology, EpiVax has now developed Ancer™, a personalized cancer vaccine platform. Ancer is a high-speed, secure, cloud-based commercial platform for processing...

Recent Posts

  • AAPS BPABC Community Presentation: In silico Immunogenicity Prediction for Protein and Peptide Therapeutics
  • IAVI Report Revisited: Lessons from HIV research for SARS-COV-2 vaccine design
  • ConvergenceRI: Truly a Beautiful Day in the Neighborhood
  • February Newsletter: Jack as Co-pilot and Zoom buddy
  • EpiVax Announces Participation in International Consortium for Development of Next-Generation Influenza Vaccines (INDIGO)

Categories

  • EpiVax Immunoncology
  • Events
  • Featured
  • News
  • Thinking Out Loud -Blog
  • Uncategorized
  • Webinars

Discover

  • Vaccine Services
  • Immunogenicity Assessment
  • Deimmunization
  • Lab Services
  • Pipeline

About

  • Our Company
  • Press Room
  • Events
  • Publication & Poster Search
  • Thinking Out Loud (Blog)
  • Contact Us

Connect

© 2021 EpiVax, Inc. – Informatics and Immunology, All rights reserved. • 188 Valley Street, Suite 424, Providence, RI 02909 • ph: 401.272.2123 • fax: 401.272.7562